Literature DB >> 8855974

Anomalous retinoblastoma protein expression in Sternberg-Reed cells in Hodgkin's disease: a comparative study with p53 and Ki67 expression.

M Sánchez-Beato1, J C Martínez-Montero, T A Doussis-Anagnostopoulou, K C Gatter, J García, J F García, E LLoret, M A Piris.   

Abstract

Retinoblastoma (Rb) tumour-suppressor protein plays a critical role in cell cycle control. Rb inactivation is a frequent phenomenon in tumours of different cell lineages, in which the absence of Rb protein has been considered to be a marker of Rb disregulation. We used modern immunohistochemical techniques to study the expression of Rb protein in a large series of 130 patients with Hodgkin's disease. Simultaneously, Western blot was used to analyse a more restricted group (12 patients) to confirm the immunohistochemical results and to clarify the phosphorylation status of Rb protein. As the level of Rb expression varied according to cell cycle stage, we also performed immunostaining for Ki67, a protein present in proliferating cells. To make comparison possible, we first characterised the amount and phosphorylation status of Rb protein in reactive lymphoid tissue and phytohaemagglutinin (PHA)-stimulated lymphocytes. The presence of p53 in Sternberg-Reed cells was also included in the study, as both proteins (p53 and Rb) have been found to be closely associated in cell cycle control. PHA-stimulated peripheral blood lymphocytes showed a parallel increase in Rb and cell cycle progression, together with progressive Rb phosphorylation. In reactive lymphoid tissue there was also a clear correlation between Rb expression and the Ki67 proliferation index (R = 0.96, P = 0.038). When analysing Hodgkin's disease samples, a clear difference emerges between cases of nodular lymphocyte predominance, which preserve the relationship between Rb and Ki67 expression (r = 0.8727, P = 0.000), and classical forms of Hodgkin's disease (nodular sclerosis and mixed cellularity), which display a strong deviation from this pattern. Two main anomalies were found: (1) One group of 21/130 cases with partial or total loss of Rb protein expression, which could reflect the existence of genetic alterations, or an altered transcriptional or translational regulation of Rb gene. (2) Another group with an abnormally high Rb/Ki67 ratio, which could support conflicting interpretations: (i) excess Rb protein for controlling cell cycle progression; or (ii) adhesion of Rb protein to other cellular or viral proteins, such as p53 and MDM2. The results of this study indicate an anomalous pattern of expression of Rb in classical forms of Hodgkin's disease, and suggest the possibility of undertaking functional studies (E1A adhesion, p16 expression) with the aim of better characterising the status of Rb protein, and correlating these findings with clinical course in Hodgkin's disease patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855974      PMCID: PMC2077106          DOI: 10.1038/bjc.1996.489

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

1.  Cytogenetic studies in untreated Hodgkin's disease.

Authors:  H Tilly; C Bastard; T Delastre; C Duval; M Bizet; B Lenormand; J P Daucé; M Monconduit; H Piguet
Journal:  Blood       Date:  1991-03-15       Impact factor: 22.113

2.  The E2F transcription factor is a cellular target for the RB protein.

Authors:  S P Chellappan; S Hiebert; M Mudryj; J M Horowitz; J R Nevins
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

Review 3.  Molecular biology of the human retinoblastoma gene.

Authors:  W H Lee; R E Bookstein; E Y Lee
Journal:  Immunol Ser       Date:  1990

4.  Retinoblastoma gene deletions in human glioblastomas.

Authors:  D J Venter; K L Bevan; R L Ludwig; T E Riley; P S Jat; D G Thomas; M D Noble
Journal:  Oncogene       Date:  1991-03       Impact factor: 9.867

5.  Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product.

Authors:  K Mihara; X R Cao; A Yen; S Chandler; B Driscoll; A L Murphree; A T'Ang; Y K Fung
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

6.  Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells.

Authors:  J M Horowitz; S H Park; E Bogenmann; J C Cheng; D W Yandell; F J Kaye; J D Minna; T P Dryja; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

7.  Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53, during cell cycle progression of normal human T cells.

Authors:  N Terada; J J Lucas; E W Gelfand
Journal:  J Immunol       Date:  1991-07-15       Impact factor: 5.422

8.  Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas.

Authors:  H J Xu; S X Hu; P T Cagle; G E Moore; W F Benedict
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

9.  Inactivation of the retinoblastoma gene in human lymphoid neoplasms.

Authors:  A M Ginsberg; M Raffeld; J Cossman
Journal:  Blood       Date:  1991-02-15       Impact factor: 22.113

10.  Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase.

Authors:  B T Lin; S Gruenwald; A O Morla; W H Lee; J Y Wang
Journal:  EMBO J       Date:  1991-04       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.